Sequential maximum androgen blockade (MAB) in minimally symptomatic prostate cancer progressing after initial MAB: two case reports

Autor: Mohan Hingorani, Sanjay Dixit, Fahim Bashir, Mohammad Butt, Simon Hawkyard, Richard Khafagy, Andrew Robertson

Publikováno v: Cancer Biology & Medicine, Vol 11, Iss 4, Pp 277-280 (2014)

The management of castrate-resistant prostate cancer progressing after maximum androgen blockade (MAB) has evolved in the last decade with the development of several novel therapeutic options. However, the initial therapeutic strategy in these patien

Externí odkaz: https://doaj.org/article/022fc90126324d13adf73edcf5739ffa

Intraperitoneal Bupivacaine versus Nalbuphine in Postoperative Pain Relief after Laparoscopic Cholecystectomy: A Randomised Clinical Study

Autor: Samiksha Khanuja, Pratibha Panjiar, Sana Hussain, Khairat Mohammad Butt

Publikováno v: Journal of Clinical and Diagnostic Research, Vol 16, Iss 2, Pp UC21-UC24 (2022)

Introduction: The rationale for using an intraperitoneal route for instilling a drug, local anaesthetic or opioid is that the exposure of peritoneum to visceral nociceptive conduction provides additional mechanism of analgesia. Aim: To compare the e

Externí odkaz: https://doaj.org/article/9baa7354936d4d5184c8758e647f42c3

Sector Free and Sub-Connected Precoding for Millimeter Wave Massive FD-MIMO Systems

Autor: Ziwei Yan, Asfandyar Awan, Shah Marjan, Mazz Mohammad Butt

Publikováno v: 2020 IEEE International Conference on Advances in Electrical Engineering and Computer Applications( AEECA).

Hybrid precoding architectures can solve the achievable sum-rate and energy consumption problems in massive MIMO systems. This makes millimeter wave (mm-Wave) as a strong contestant to enable magnitude greater spectrum than current cellular frequency

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0eb301588060302f4142caa8778ef8dc
https://doi.org/10.1109/aeeca49918.2020.9213459

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE) : 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Autor: Jane Brown, Roshan Agarwal, Catherine Harper-Wynne, A. Humphreys, Eliot Sims, Peter Hall, Mukesh Mukesh, Sundus Yahya, Nawaz Walji, Mojca Persic, Donna L. Howe, Simon Waters, Wendy Taylor, Anita Chhabra, Karen Tipples, Helen Innes, Mark Churn, Peter Ostler, Pamela Woodings, Helen Roe, Lisa H Barraclough, Shrushma Loi, Maggie Wilcox, Susan Lupton, Adrian Harnett, Rebecca Bowen, Peter Simmonds, Natasha Mithal, H. M. Earl, Apurna Jegannathen, Kathryn Wright, A.S. Dhadda, Rozenn Allerton, Jean Abraham, Karen McAdam, Ioannis Gounaris, Mohini Varughese, Mark Harries, Helen Neville-Webbe, Catherine Bale, Narottam Thanvi, Carolyn Bedi, Carlos Caldas, Fharat A. Raja, Helena M. Earl, David Miles, Trevor McGolick, Andrew D. Goodman, Kerry Raynes, Anthony Neal, Richard Simcock, Hartmut Kristeleit, Carol MacGregor, Christopher McCabe, Caroline Archer, Laura Pettit, Chris Bradley, Anne-Laure Vallier, Urmila Barthakur, Perric Crellin, S O'Reilly, Betania Mahler Araujo, Andrew Eichholz, Louise Hiller, Anne Rigg, Janine Mansi, Jacqueline Newby, Janet A. Dunn, Sarah Smith, Chris Plummer, Jennifer Marshall, Aian Moss, Zafar Malik, Larry Hayward, Mohammad Butt, Andrew M Wardley, Anup Vinayan, Shiroma De Silva-Minor, Mei-Lin Ah-See, Sue Down, Helen B Higgins, Catherine Reed, Kim Benstead, Rakesh Mehra, Luke Hughes-Davies, David Cameron, Daniel Nelmes, O.S. Din, Charlotte Moss, Daniel Epurescu, Anne C Armstrong, Nicola Storey, David J. Eaton, Hafiz Algurafi, Mariam Jafri, Daniel Rea, Nihal Shah, Elena Provenzano, Susan Cleator, Muireann Kelleher, Claire Hulme, Daniela Lee, D. Bloomfield, Margaret Daly, Joanne Cliff, Chee Goh, Sanjay Raj, Maher Hadaki, Jayant S. Vaidya, Robert Grieve

Publikováno v: Earl, H M, Hiller, L, Vallier, A-L, Loi, S, McAdam, K, Hughes-Davies, L, Harnett, A N, Ah-See, M-L, Simcock, R, Rea, D, Raj, S, Woodings, P, Harries, M, Howe, D, Raynes, K, Higgins, H B, Wilcox, M, Plummer, C, Mansi, J, Gounaris, I, Mahler-Araujo, B, Provenzano, E, Chhabra, A, Abraham, J E, Caldas, C, Hall, P S, McCabe, C, Hulme, C, Miles, D, M Wardley, A & Cameron, D A & Dunn, J A 2019, ' 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial ', The Lancet, vol. 393, no. 10191, pp. 2599-2612 . https://doi.org/10.1016/S0140-6736(19)30650-6
Lancet (London, England)

Background: Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast cancer. The standard treatment duration is 12 months but shorter treatment could provide similar efficacy while reducing toxicities and cost

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd37138df2c42b14428f44dc7b4ec95b
http://wrap.warwick.ac.uk/118352/2/WRAP-6-versus-12-months-adjuvant-trastuzumab-HER2-positive-early-breast-cancer(PERSEPHONE)-Dunn-2019.pdf

Bacteriological assessment of drinking water of Islamabad Capital Territory, Pakistan

Autor: Toqeer Ahmed, Noor Mohammad Butt, Saba Imdad

Publikováno v: Desalination and Water Treatment. 56:2316-2322

This study was conducted to evaluate the bacteriological quality of drinking water of tube wells, filtration plants, and water supplies from various sectors of Islamabad Capital Territory (ICT), Pakistan. Fifty-five water samples were collected from

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b11e4750a61f7bb55a68c319285a52b7
https://doi.org/10.1080/19443994.2014.963154